Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Randomized, Double-blinded, Placebo-controlled, Multicenter Phase III Study Comparing Bevacizumab Plus Carboplatin/Paclitaxel Versus Placebo Plus Carboplatin/Paclitaxel in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy For Advanced Disease
Verified date | February 2018 |
Source | Hoffmann-La Roche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of bevacizumab (Avastin) versus placebo in combination with carboplatin/paclitaxel in participants with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy for advanced disease. Participants will be randomized to receive either bevacizumab 15 milligrams per kilogram (mg/kg) intravenously (IV) or placebo on Day 1 of each 3 week cycle, plus up to 6 cycles of carboplatin/paclitaxel. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs. After progression, participants in the bevacizumab arm may continue to receive bevacizumab in combination with approved second- and third-line treatment at the discretion of the investigator, up to the third progression.
Status | Completed |
Enrollment | 276 |
Est. completion date | August 17, 2017 |
Est. primary completion date | January 27, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Locally advanced (Stage IIIb not amenable for combined modality treatment), metastatic (Stage IV) or recurrent non-squamous non-small cell lung cancer - Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 - Adequate hematological, renal and liver function Exclusion Criteria: - Prior chemotherapy or treatment with another systemic anti-cancer agent for the treatment of the participant's current stage of the disease (Stage IIIb, IV or recurrent disease) - Mixed non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component - Evidence of tumor invading major blood vessels on imaging - Central nervous system (CNS) metastases, even if previously treated - History of hemoptysis in the 3 months prior to enrollment - History or evidence of inherited bleeding diathesis or coagulopathy - Uncontrolled hypertension and/or history of hypertensive crisis or hypertensive encephalopathy - Clinically significant cardiovascular or vascular disease - Malignancies other than non-small cell lung cancer within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or localized prostate cancer or ductal carcinoma in situ treated surgically with curative intent |
Country | Name | City | State |
---|---|---|---|
China | Beijing Cancer Hospital | Beijing | |
China | Beijing Chest Hospital; Oncology Department | Beijing | |
China | Beijing Hospital of Ministry of Health; Hematology | Beijing | |
China | General Hospital of Chinese PLA; Department of Hematology | Beijing | |
China | The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA) | Beijing | |
China | The Second Xiangya Hospital of Central South University | Changsha | |
China | West China Hospital, Sichuan University | Chengdu | |
China | Guangdong General Hospital | Guangzhou | |
China | The First Affiliated Hospital of Guangzhou Medical University | Guangzhou | |
China | Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University | Hangzhou | |
China | Harbin Medical University Cancer Hospital | Harbin | |
China | Jiangsu Cancer Hospital | Nanjing | |
China | Guangxi Cancer Hospital of Guangxi Medical University | Nanning | |
China | Fudan University Shanghai Cancer Center | Shanghai | |
China | Shanghai chest hospital | Shanghai | |
China | Shanghai Pulmonary Hospital | Shanghai | |
China | Cancer Hospital of Shantou University Medical College | Shantou |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-Free Survival (PFS) as Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.0 (RECIST v1.0) Criteria | Baseline up to death or disease progression, whichever occurs first (up to approximately 20 months) | ||
Secondary | Overall Survival (OS) | Baseline up to death (up to approximately 35 months) | ||
Secondary | Percentage of Participants Who are Alive at Year 1 | Year 1 | ||
Secondary | Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed Using RECIST v1.0 Criteria | Baseline up to death or disease progression, whichever occurs first (up to approximately 35 months) | ||
Secondary | Duration of Response as Assessed Using RECIST v1.0 Criteria | Baseline up to death or disease progression, whichever occurs first (up to approximately 35 months) | ||
Secondary | Percentage of Participants With Adverse Events | From baseline up to approximately 35 months | ||
Secondary | PFS as Assessed Using RECIST v1.0 Criteria in Subgroups Defined by Vascular Endothelial Growth Factor-A (VEGF-A) High/Low Level Expression at Baseline | Baseline up to death or disease progression, whichever occurs first (up to approximately 35 months) | ||
Secondary | PFS as Assessed Using RECIST v1.0 Criteria in Subgroups Defined by Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) High/Low Level Expression at Baseline | Baseline up to death or disease progression, whichever occurs first (up to approximately 35 months) | ||
Secondary | OS in Subgroups Defined by VEGF-A High/Low Level Expression at Baseline | Baseline up to death (up to approximately 35 months) | ||
Secondary | OS in Subgroups Defined by VEGFR-2 High/Low Level Expression at Baseline | Baseline up to death (up to approximately 35 months) | ||
Secondary | Percentage of Participants With Objective Response of CR or PR as Assessed Using RECIST v1.0 Criteria in Subgroups Defined by VEGF-A High/Low Level Expression at Baseline | Baseline up to death or disease progression, whichever occurs first (up to approximately 35 months) | ||
Secondary | Percentage of Participants With Objective Response of CR or PR as Assessed Using RECIST v1.0 Criteria in Subgroups Defined by VEGFR-2 High/Low Level Expression at Baseline | Baseline up to death or disease progression, whichever occurs first (up to approximately 35 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |